S. Karger AG

SHERPA: Unknown

People

  1. Bodei
    Bodei
  2. Drilon
    Drilon
  3. Motzer
    Motzer
  4. Abou-Alfa
    Abou-Alfa
  5. Chaganti
    Chaganti
  6. Lin
    Lin
  7. Janjigian
    Janjigian
  8. Jhanwar
    Jhanwar
  9. Tang
    Tang
  10. Clarkson
    Clarkson

Groups

  1. Department of Medicine (280)
  2. Solid Tumor Oncology Division (160)
  3. Hematologic Malignancies, Division of (107)
  4. Center for Hematologic Malignancies (103)
  5. Survivorship Research (59)
  6. Gastrointestinal Oncology Service (57)
  7. Sloan Kettering Institute Postdocs (55)
  8. Surgery (54)
  9. Thoracic Oncology (45)
  10. Department of Pathology and Laboratory Medicine (43)
Search Within
Formats
  1. Meeting Abstract (332)
  2. Journal Article (255)
  3. Book Section (20)
  4. Review (16)
  5. Conference Paper (10)
  6. Book Whole (1)
  7. Editorial (1)
Groups
  1. Department of Medicine (280)
  2. Solid Tumor Oncology Division (160)
  3. Hematologic Malignancies, Division of (107)
  4. Center for Hematologic Malignancies (103)
  5. Survivorship Research (59)
  6. Gastrointestinal Oncology Service (57)

More Groups

People
  1. Lisa Bodei (32)
  2. Alexander Drilon (23)
  3. Robert Motzer (23)
  4. Ghassan Abou-Alfa (18)
  5. Steven Hajdu (18)
  6. Oscar Lin (16)

More People

Years
  1. 2025 (5)
  2. 2024 (21)
  3. 2023 (37)
  4. 2022 (42)
  5. 2021 (31)
  6. 2020 (51)

More Years

Publications
  1. Oncology Research and Treatment (226)
  2. Cytogenetics and Cell Genetics (61)
  3. Acta Cytologica (58)
  4. Neuroendocrinology (51)
  5. Acta Haematologica (32)
  6. Onkologie (19)

More Publications

Results (635)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: results from the randomized phase 3 CELESTIAL trial
    Meeting Abstract

    Waidmann, O.; Abou-Alfa, G. K.; Meyer, T.; Cheng, A. L.; El-Khoueiry, A. B.; Rimassa, L.; Ryoo, B. Y.; Cicin, I.; Merle, P.; Chen, Y. H.; more...
    Oncology Research and Treatment (2018)

    Fulltext@MSK | Save
  • Quantification of drug synergism in vivo exemplified for the combination of Taxotere and T607 against colon carcinoma HCT-116 xenograft tumors in nude mice
    Meeting Abstract

    Ulrich-Merzenich, G.; Fu, J.; Chou, J. H.; Chou, T. C.
    Oncology Research and Treatment (2018)

    Fulltext@MSK | Save
  • CheckMate 227: Nivolumab (Nivo) + ipilimumab (Ipi) vs platinum-doublet chemotherapy (Chemo) as first-line treatment for advanced non-small cell lung cancer (NSCLC) with high tumor mutational burden (TMB)
    Meeting Abstract

    Reck, M.; Hellmann, M. D.; Paz-Ares Rodriguez, L.; Ramalingam, S. S.; Brahmer, J.; O'Byrne, K. J.; Bhagavatheeswaran, P.; Nathan, F.; Borghaei, H.
    Oncology Research and Treatment (2018)

    Fulltext@MSK | Save
  • Outcomes in patients (pts) who had received sorafenib (S) as the only prior systemic therapy in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC)
    Meeting Abstract

    Venerito, M.; Kelley, R. K.; Ryoo, B. Y.; Merle, P.; Park, J. W.; Bolondi, L.; Chan, S. L.; Lim, H. Y.; Baron, A.; Parnis, F.; more...
    Oncology Research and Treatment (2018)

    Fulltext@MSK | Save
  • Outcomes based on age in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC)
    Meeting Abstract

    Venerito, M.; Rimassa, L.; Cicin, I.; Blanc, J. F.; Klümpen, H. J.; Zagonel, V.; Tran, A.; Kim, S.; Lin, Z. Z.; Tam, V. C.; more...
    Oncology Research and Treatment (2018)

    Fulltext@MSK | Save
  • Clinicogenetic risk factors in patients receiving autologous stem-cell transplantation after frontline R-CHOP for advanced follicular lymphoma: An analysis from the GLSG2000 trial
    Meeting Abstract

    Alig, S.; Pastore, A.; Jurinovic, V.; Bararia, D.; Häbe, S.; Passerini, V.; Keay, W.; Hellmuth, J.; Rosenwald, A.; Klapper, W.; more...
    Oncology Research and Treatment (2018)

    Fulltext@MSK | Save
  • Ibrutinib/rituximab versus placebo/rituximab in Waldenström's macroglobulinemia (WM): Results of a randomized phase 3 trial
    Meeting Abstract

    Buske, C.; Tedeschi, A.; Trotman, J.; García-Sanz, R.; MacDonald, D.; Leblond, V.; Mahe, B.; Herbaux, C.; Tam, C. S.; Palomba, M. L.; more...
    Oncology Research and Treatment (2018)

    Fulltext@MSK | Save
  • Clinical outcomes by nephrectomy status in METEOR, a randomized phase 3 trial of cabozantinib (cabo) vs everolimus (eve) in patients (pts) with advanced renal cell carcinoma (RCC)
    Meeting Abstract

    Schmidinger, M.; Tannir, N. M.; Powles, T.; Escudier, B. J.; Donskov, F.; Grünwald, V.; Sternberg, C. N.; Schoffski, P.; Szczylik, C.; Peltola, K. J.; more...
    Oncology Research and Treatment (2018)

    Fulltext@MSK | Save
  • Outcomes based on age in the phase 3 METEOR trial of cabozantinib (cabo) vs everolimus (eve) in patients with advanced renal cell carcinoma (RCC)
    Meeting Abstract

    Bergmann, L.; Donskov, F.; Motzer, R. J.; Voog, E.; Hovey, E. J.; Grüllich, C.; Nott, L. M.; Cuff, K. E.; Gil, T.; Jensen, N. V.; more...
    Oncology Research and Treatment (2018)

    Fulltext@MSK | Save
  • Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib (c) vs everolimus (e) in advanced renal cell carcinoma (RCC)
    Meeting Abstract

    Grüllich, C.; Powles, T.; Motzer, R. J.; George, D. J.; Jonasch, E.; Pal, S. K.; Tannir, N. M.; Signoretti, S.; Mai, T. H.; Scheffold, C.; more...
    Oncology Research and Treatment (2018)

    Fulltext@MSK | Save